Dermatology

Below are current clinical trials.

Filter this list of studies by location, status and more.

1. Patient Satisfaction in Mohs Micrographic Surgery with Supplemental Lidocaine Jelly

   Scottsdale/Phoenix, Ariz.

   The purpose of this study is to assess how using lidocaine jelly in Mohs surgery impacts 1) the overall quantity of lidocaine/epinephrine injectable needed to maintain anesthesia, and 2) patients’ pain/anxiety associated with anesthesia injections.   

2. Tissue Repository for Non-melanoma Skin Cancers

   Scottsdale/Phoenix, Ariz., Rochester, Minn.

   The purpose of this repository is to collect tissue and blood specimens of non-melanoma skin cancers for future studies. The aim is to create a single, annotated bio-repository of non-melanoma skin cancers. Additionally, we may create cell lines and patient derived tumors from collected samples. This is a highly significant first step to understand the underlying drivers of disease.

    

    

3. Oncogene-­-Induced Secretion of Extracellular Matrix Proteins in Squamous Cell Carcinoma of the Skin

   Rochester, Minn.

   The purpose of this study is:

   Define a set of differentially regulated secreted proteins in human cancer cells across all stages of cancer progression

   • Identify a set of 32 genes (including housekeeping genes) that encode for secreted proteins that correlate with disease progression using a bioinformatics approach
   • Design probe sets for RT-PCR and run a pilot study both on FFPE and fresh tissue
   • If the pilot is successful, expand the data set to an n of 100. Include SCCs of various differentiation and anatomical location. Include SCCs from transplant patients.

   Correlate the results of the RT-PCR panel to the biological behavior of the tumor

   • The following variables will be examined:
     • Differentiation
     • Ability to metastasize
     • Response to therapy

4. Valchlor in the Treatment of Lichen Planopilaris

   Jacksonville, Fla.

   The primary objective of this study is to assess the potential effectiveness of once daily application of Valchlor in decreasing disease activity in patients with Lichen Planopilaris. The primary measurement of efficacy will be with the Lichen Planopilaris Activity Index (LPPAI) before and after 6 months of treatment. Secondary measures of efficacy will be the mean follicular density, Physician Global assessment (PGA) score, and the Dermatology Quality of Life Index (DQLI) score before and after six months of therapy.

5. A Study to Collect Long-Term Data on Pediatric Cutaneous Mastocytosis

   Rochester, Minn.

   The purpose of this study is to develop a registry to collect long-term data on patients with pediatric cutaneous mastocytosis, and develop better knowledge of the timing, symptoms, resolution or progression of the disease, and predictive markers of its severity.

6. Development of an Evidence-Based Decision Aid for Acne Treatment

   Rochester, Minn.

   The purpose of this study is to identify the key elements of the clinical discussion between patients and clinicians regarding acne treatment and to develop an evidence-based decision aid for acne treatment. 

7. A Study of Phenotypic and Genetic Analysis of Vascular Overgrowth Syndromes

   Rochester, Minn.

   The purpose of this research is to develop a better understanding of the cause of vascular overgrowth syndromes and to develop a clinically relevant classification system. The researchers will also seek to determine if there is a relationship between the specific gene mutation and the clinical features (genotype-phenotype correlation).

8. Evaluating the Effectiveness of Apremilast in the Treatment of Subjects with Canker Sores

   Jacksonville, Fla.

   The purpose of this study is to determine whether Apremalast is an effective treatment for patients with recurring canker sores.

9. A Study to Evaluate the Effectiveness, Safety and Tolerability of PF-06823859 In Adults With Moderate-to-Severe Dermatomyositis

   Jacksonville, Fla.

   The purpose of this study is to evaluate the investigational drug PF-06823859 and a placebo administered to adult pPatients with moderate-to- severe Dermatomyositis.

10. A Study of Cemiplimab in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy

    Scottsdale/Phoenix, Ariz., Jacksonville, Fla., Rochester, Minn.

    The primary objective is to estimate the overall response rate (ORR) for metastatic Basal Cell Carcinoma (BCC) (group 1) and for unresectable locally advanced BCC (group 2) when treated with Cemiplimab as a monotherapy.